Discovery and optimization of pyrrolopyrimidines as highly potent, selective and brain-penetrant LRRK2 inhibitors
- 17 November 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (1) , 676-685
Abstract
In this study, we report the optimization of screening hit 1 to the selective brain-penetrant LRRK2 inhibitor 39.Keywords
This publication has 17 references indexed in Scilit:
- LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's DiseaseMovement Disorders, 2023
- LRRK2 and idiopathic Parkinson’s diseaseTrends in Neurosciences, 2022
- Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's diseaseCurrent Opinion in Cell Biology, 2020
- Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitorsBioorganic & Medicinal Chemistry Letters, 2018
- Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitorsBioorganic & Medicinal Chemistry Letters, 2017
- Parkinson diseaseNature Reviews Disease Primers, 2017
- Parkinson's diseaseThe Lancet, 2015
- Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylationJournal of Pharmaceutical and Biomedical Analysis, 2013
- GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitorBioorganic & Medicinal Chemistry Letters, 2012
- A common LRRK2 mutation in idiopathic Parkinson's diseaseThe Lancet, 2005